The TRAF2 and TRAF6 expression in myomas and myometrium of women in reproduction and perimenopausal age. by Plewka, Andrzej et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2010:48(3): 407 (407-416) 
10.2478/v10042-010-0039-6
Introduction
Despite the high frequency of leiomyoma manifesta-
tion scanty information is available on their develop-
ment and growth. On the basis of biochemical and
cytogenetic studies every leiomyoma is thought to rep-
resent a product of clonal expansion of an individual
myocyte [1-3]. Just as it is the case with other tumours,
probably several genetically sensitive sites exist,
which lead to dysregulation of a smooth muscle cell,
resulting in its transformation to the common pheno-
type of a leiomyoma cell.
Studies performed till now demonstrated that an
immune response is linked to activation of NF-κB
under effect of IL-1 and TNF-α [4-8]. The two
cytokines exert their effect due to activation of 
a kinase which induces NF-κB and, then, kinase IκB,
which directly affects activity of NF-κB transcription
factor. The phosphorylated, C-terminal domain of IL-1
receptor-linked kinase interacts with TRAF6 protein
[9-11]. Transmission of IL-1 signal may include role of
TRAF6 and/or TRAF2 [12-14]. TRAF-6 activates
NIK kinase but it should be stressed that NIK is a com-
mon mediator of signalling pathways originating from
multiple cytokine receptors [15-17].
TRAF (TNF receptor-associated factor) family rep-
resents a family of cytoplasmic proteins capable both
of negative control of apoptosis and of induction of
genes which promote survival. They were shown to
serve as adaptor proteins for a broad range of surface
receptors, to play an important role not only in apop-
tosis but also in response to stress. The proteins may
directly interact with intracellular domains of surface
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receptors, including TNF-α (TRAF2) or IL-1β
(TRAF6) receptors. 
TRAF proteins may serve for modulation of recep-
tors capacities to mobilize various signalling path-
ways, which lead to phosphorylation and activation of
protein kinases and, then, to activation of transcription
factors of Rel and AP-1 family. 
In our earlier study we evaluated expression of aro-
matase in uterine myomas [18]. Expression of the aro-
matase depends on several factors, including TRAF.
Even if neither TRAF2 nor TRAF6 directly affect
expression of aromatase, their indirect effect is evi-
dent. The two proteins are known to directly stimulate
activity of NF-κB. This nuclear factor may bind one of
the promoters, such as I.4, which mobilizes aromatase
synthesis pathway. Expression of aromatase may also be
stimulated by PII promoter. While the promoter is acti-
vated by PGE2, levels of the prostaglandin are is direct-
ly related to activity of COX-2, and activity of the
cyclooxygenase is stimulated, among others, by NF-κB. 
In this aim the attempt will be undertaken to
demonstrate whether there exist differences in the
amount and distribution of TRAF2 and TRAF6 pro-
teins in myomas of various size, isolated from women
of various age, as compared to an unchanged tissue.
The evaluation will be made using Western blot tech-
nique and quantitative analysis of immunohistochemi-
cal tests conducted on tissues of a normal uterus and 
a myomatous uterus.
Materials and methods
Human material. Recruitment of patients, clinical studies and
hormonal tests will be conducted in the Chair and Department of
Gynaecological Endocrinology, Medical University of Silesia in
Katowice while enzymatic and protein studies will be executed in
the Department of Proteomics.
The studies were conducted on 40 patients with myomas, at the
reproductive age (below 45th year of age, FSH<30 mIU/ml;
Samales were taken in follicular phase of menstrual cycle) and 
40 patients with myomas in the perimenopausal age (45-55 years
of life, FSH>30 mIU/ml). Inclusion criteria will involve myoma
detected by USG, qualification of the patient to hysterectomy,
informed consent to the planned studies. The exclusion criteria will
include: therapy with any drugs, including hormonal drugs in the
minimum of 3 months before inclusion to the studies, neoplastic
disease, endometrial hypertrophy, metabolic and systemic distur-
bances, nicotinism. 
Myometrial samples, for use as health controls were taken
from 10 young women (<40 years old) undergoing hysterectomies
for ovary tumors and 10 perimenopausal age women (>52 years
old) undergoing hysterectomies for uterine prolapse. 
In these studies we used only material from uteruses with one
large myomas or one large and few small myomas. The material
for studies was excised from uterus taken during surgery, and fixed
histopathologically. Samples of leyomyoma 1 × 1 cm and samples
of a similar size from health myometrium at the distance of at least
4 cm each were taken. Before isolation of myometrium samples the
patients were informed on the aim of the studies. The planned
investigative procedures were approved by the Medical Bioethical
Commission.
Characteristics of studied groups
Group 1. Myometrium of menstruating women, in whom hys-
terectomy was performed for reasons other than uterine leiomy-
omas; the 10 patients represented the lesion-free control.
Group 2. Leiomyomas of <3 cm in diameter, sampled from
uteri of menstruating women (n=20 women).
Group 3. Myometrium of menstruating women, sampled at the
distance of not less than 4 cm from margins of a small leiomyoma
(n=20 women; autologous control).
Group 4. Leiomyomas of >5 cm in diameter, sampled from
uteri of menstruating women (n=20 women).
Group 5. Myometrium of menstruating women, sampled at the
distance of not less than 4 cm from margins of a large leiomyoma
(n=20 women; autologous control).
Group 6. Myometrium of non-menstruating women, in whom
hysterectomy was performed for reasons different than uterine
leiomyomas (n=10 women; lesion-free control).
Group 7. Leiomyomas of <3 cm in diameter, sampled from
uteri of non-menstruating women (n=20 women).
Group 8. Myometrium of non-menstruating women, sampled
at the distance of not less than 4 cm from margins of a small
leiomyoma (n=20; autologous control).
Group 9. Leiomyomas of >5 cm in diameter, sampled from
uteri of non-menstruating women, (n= 20 women).
Group 10. Myometrium of non-menstruating women, sampled
at the distance of not less than 4 cm from margins of a large
leiomyoma (n=20 women, autologous control).
Immunohistochemistry. Tissues were fixed in 4% buffered for-
malin, dehydrated and then embedded in paraffin. Section (5 μm)
were mounted on silane-coated slides. Samples were de-waxed,
and rehydrated. To unmask the antigen, sections were boiled in
0,01 M citrate buffer, pH 6, in a microwave oven for 10 min at 800
W. Endogenous peroxidase activity was quenched using 1.5% (v/v)
solution H2O2 in methanol for 10 min and then washed in PBS-
Tween 20 (0,05% v/v) and blocked with 1% BSA for 60 min. The
sections were further blocked with avidin-biotin-blocking solution
according to the manufacturer's instruction. After this the slides
were incubated with rabbit anti-TRAF2 polyclonal antibody
(Abcam) or rabbit anti-TRAF6 monoclonal antibody (Abcam) in 
a humidified chamber for 22 h at 4°C. After washing in PBS-
Tween 20 sections were incubated with biotinylated goat anti-rab-
bit immunoglobulins (Vector Laboratories Inc.) for 30 min, and
were incubated with avidin-biotinylated peroxidase complex (Vec-
tor) for 30 min. The bound antibodies were visualised with
diaminobenzidine (DAB) and H2O2 in PBS, pH 7,5 according to
supplier's instructions (Vector). Finally, the tissues were stained
with Gill's hematoxilin, dehydrated, and cover-slipped. For nega-
tive controls rabbit IgG were used. 
In each positively stained cell, the intensity of staining was
measured as the optical density of the reaction product, with the
program KS 300 VIDAS video image analyzer served by IBAS
2.5 system and a Panasonic digital camera. For each analyzed
area, 173 × 130 μm average optical density per unit area was cal-
culated. Finally, the arithmetic mean and standard deviation were
calculated.
Western blotting. Tissue samples (~500 mg) were homoge-
nized in 0.5 % Triton X-100 lysis buffer containing 20 mM Tris-
HCl (pH 7.5), 150 mM NaCl, 10 mM NaF, 2 mM  dithiothreitol
(DTT), 1mM sodium orthovanadate, 1mM phenylmethylsulfonyl
floride (PMSF) and 20 M aprotinin. Homogenates were cen-
trifuged at 10,000 × g for 10 min. Concentration of protein was
determined by Bradford assay. For immunoblotting samples (25
μg of protein) were separated by 12% SDS-polyacrylamide gels,
and transferred to nitrocellulose membranes. After blocking with
5% skim milk in PBS-T (PBS with 0.1% Tween 20)  for 1h, the
membranes were probed with TRAF2 or TRAF6 antibodies
(Abcam) overnight. Primary antibodies were detected with
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biotinylated anti-rabbit IgG made in goat (Vectastain ABC-AmP
Vector Laboratories, Inc.) (30 min) and with streptavidin and
biotinylated alkaline phospatase complex (30 min) and developed
using a nitroblue tetrazolium and 5-bromo-4-3-indolylphosphate
(Vector Laboratories, Inc.). Subsequent Western blotting analyses
were performed.
Statistical analysis. Normal distribution of the data was confirmed
by the Kolmogorov-Smirnov test. Results are presented as a mean
± SD. The Student's t-test or the Mann-Whitney U-test were per-
formed where appropriate. To estimate correlation between TRAFs
expression, myomas and age of women we used Spearman's rank
correlation test. A p value <0.05 was considered statistically sig-
nificant.
Results
Immunohistochemical studies
Optical density of cells with expression of an evaluated
protein reflects concentration of the immunocytochem-
ical reaction product in evaluated uterine structures. 
TRAF2
Young women
Evaluating levels of TRAF2 in studied structures
(Fig. 1), optical density of the immucytochemical
reaction products in small myomas of young women
was found to be higher, amounting to around 185% of
the control level (Fig. 2). The same analysis targeted at
vicinity of the myomas demonstrated also higher
expression of the protein, which in this case reached
152% of the control level. Analysis of the data showed
that expression of TRAF2 at the periphery of myomas
amounted to 82% of the value noted in the myoma.
Comparing optical density in large myomas mani-
festing TRAF2 expression with the control level the
demonstrated expression of the protein was found to
be equal to 196% of the control level. Similarly to
small myomas, TRAF2 level measured at the periph-
ery was slightly lower than that in the myomas,
amounting to 182% of the control level. This corre-
sponded to 93% of TRAF2 expression level noted in
large myomas. 
In women of reproductive age, TRAF2 expression
level in large uterine myomas resembled the value
noted in small myomas. Evaluation of the protein
expression at the direct periphery of the large myomas
demonstrated a similar expression level to that noted at
the periphery of small myomas.
Women at perimenopausal age
Evaluation of TRAF2 level in studied structures (Fig. 1)
showed that in women of perimenopausal age optical
density of the reaction product in small myomas was
increased to almost 165% of the control level (Fig. 2).
Analysis of myoma periphery demonstrated the level
higher than in the control (150% of the control level).
Analysis of the data disclosed that expression of TRAF2
at the periphery of small myomas constituted 92% of the
value observed inside the myomas.
Evaluating optical density in large myomas with
TRAF2 expression as compared to the control, the for-
mer was found to manifest higher expression of the
protein, amounting to almost 175% of the control
level. In contrast to small myomas, activity of TRAF2
measured at the periphery was lower than inside the
myoma and amounted to around 147% of the control
level. 
Analysis of TRAF2 expression in uterine myomas
of women of post-reproductive age disclosed that in
large myomas expression of TRAF2 was comparable
to the expression documented in small myomas. At the
direct vicinity of large myomas the expression resem-
bled that observed around small myomas. 
Effect of age
Evaluating content of TRAF2 reaction product, a level
of the protein in control samples obtained from young
women was slightly lower than in women of peri-
menopausal age women. A similar observation was
made upon quantitation of the protein expression in
small myomas and at their periphery in women of the
two age groups. 
Analysis of the quantitative data related to large
myomas demonstrated that in women of peri-
menopausal age TRAF2 expression level was lower
and amounted to 89% of the level detected in young
women. Also at the periphery of large myomas the
level was distinct in the two age groups: in young
women it amounted to 124% of the value observed in
the older group.
TRAF6
Young women
Upon evaluation of TRAF6 levels in the studied struc-
tures (Fig. 3), in young women optical density of the
immunocytochemical reaction product was increased in
small myomas, reaching around 235% of the control
level (Fig. 4). The same analysis targeted at the myoma
periphery also in this case demonstrated expression of
the protein higher than in the control, reaching the level
of 185%. Analysis of the data demonstrated that expres-
sion of TRAF6 at the periphery of myoma amounted to
78% of the value noted in the myoma.
Comparing optical density of large myomas with
TRAF6 expression with the control level, the protein
expression was found to represent 288% of the control
value. Similarly to small myomas, TRAF6 expression
level measured at the periphery was slightly lower than
that in myomas and corresponded to 166% of the con-
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trol level or 58% of the expression of TRAF6 noted in
large myomas. 
Quantitative analysis of TRAF6 expression level in
uterine myomas of women in reproductive age, in
large myomas the expression level was higher than
that observed in small myomas, amounting to 123% of
the protein expression level in small myomas. In direct
vicinity of large myomas the expression level was
lower than the level noted around small myomas, cor-
responding to 90% of the latter level. 
Women of perimenopausal age
Evaluation of TRAF6 expression level in the studied
structures (Fig. 3) disclosed that in women of peri-
menopausal age optical density of the reaction product
increased in small myomas to almost 210% of the con-
trol level (Fig. 4). At periphery of the myomas expres-
sion of the protein also was higher than in the control,
reaching the level equivalent to 195% of the control.
Analysis of the data showed that TRAF6 expression at
periphery of small myomas reached 95% of the value
observed in the myomas.
Evaluation of optical density of large myomas with
TRAF6 expression showed that the expression was
higher, corresponding to 240% of the control level. Sim-
ilarly to small myomas TRAF6 activity measured at
periphery was slightly lower than that in the myomas,
amounting to around 222% of the control value. 
Analysis of TRAF6 expression in uterine myomas
of women in post-reproductive age demonstrated that
in large myomas TRAF6 expression was higher as
compared to the expression observed in small
myomas. In a direct vicinity of large myomas it was
found to be slightly higher than the level noted in
vicinity of small myomas. 
Effect of age
Comparison of the product content in the reaction for
TRAF6 showed levels of the protein in control sam-
ples originating from young women was slightly high-
er than the level observed in perimenopausal women.
A similar observation was made during quantitative
evaluation of the protein expression in small myomas.
Periphery of small myomas demonstrated similar val-
ues of TRAF6 expression in the two age groups of
women. 
Analysis the quantitative data related to large
myomas demonstrated that TRAF6 expresssion level in
women of perimenopausal age was lower, amounting to
83% of the level demonstrated in young women. The
reaction product measured in vicinity of large myomas
was also distinct in the two age groups: in young women
it amounted to 75% of the value observed in the older
group.
Western blot analysis
TRAF2
Upon comparison of TRAF2 expression in myometri-
um of women of various age the samples originating
from women in perimenopausal age were found to be
slightly higher, although the difference failed to reach
statistical significance. 
For a better and a more legible evaluation of
changes in TRAF2 expression (and the remaining pro-
teins evaluated by Western blot analysis) a quantitative
analysis was performed exclusively in the same age
groups, in every case accepting the expression value
noted in a pure control as 100%.
Expression of TRAF2 measured at the periphery of
myomas originating from uteri of young females was
higher than that in the control, amounting to 115% and
120% (Fig. 5; Table 1) in, respectively small and large
myomas although the differences proved insignificant.
The TRAF2 expression level detected in small
myomas isolated from uteri of young women was
clearly higher than in the control and amounted to
135%, and the difference was significant. Even higher
was TRAF2 expression level detected in large
myomas, in which the expression level reached 140%
of the control level. 
Upon analysis of differences in TRAF2 expression
between myomas and their direct vicinity expression
of the protein in small myomas was significantlly
higher than that in the surrounding myometrium. 
A similar difference in the level of TRAF2 expression
was detected in cases of large myomas.
Analysis of differences in TRAF2 expression in
uteri of perimenopausal women demonstrated simi-
lar but slightly more accentuated differences:
expression of the protein measured at the periphery
of myomas was also higher than that in the control.
The levels amounted to 125% and 120% in small and
large myomas, respectively (Fig. 5; Table 1), but also
in this case the differences proved to be insignifi-
cant.
Expression level of the evaluated TRAF2 protein
in small myomas isolated from uteri of peri-
menopausal women was higher than that in the con-
trol and reached 145%, and the difference was sig-
nificant. In large myomas of the age group TRAF2
expression level was even higher, amounting to
160% of the control level. 
Evaluating TRAF2 expression level in myomas
and in the surrounding myometrium it was shown
that in the older age group expression of TRAF2 in
small myomas was significantly higher than that in
the surrounding myometrium. An even higher differ-
ence, of 135% order was disclosed during analysis of
differences in TRAF-2 expression levels in large
myomas.
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Fig. 1. Immunohistochemical staining of uterini samples from reproductive (A-E) and
perimenopausal age women (F-J) with rabbit anti-TRAF2 polyclonal antibodies. A and F
– healthy myometrium, B and G – small myomas, C and H – periphery of small myomas,
D and I – large myomas, E and J – periphery of large myomas (original magnification
×200). 
Fig. 2. Quantitative evaluation of
TRAF2 expression in immunohisto-
chemical staining. Date shown repre-
sent mean ± SD.
Differences in TRAF2 expression: * –
in reproductive age women and peri-
menopausal age women; a – in small
myomas and healthy myometrium; b –
in periphery of small myomas and
healthy myometrium; c – in large
myomas and healthy myometrium; d –
in periphery of large myomas and
healthy myometrium; e – in small
myomas and its periphery; f – in small
myomas and its periphery, are statisti-
cally significant.
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Fig. 3. Immunohistochemical staining of uterini samples from reproductive (A-E) and
perimenopausal age women (F-J) with rabbit anti-TRAF6 polyclonal antibodies. A and F
– healthy myometrium, B and G – small myomas, C and H – periphery of small myomas,
D and I – large myomas, E and J – periphery of large myomas (original magnification
×200).
Fig. 4. Quantitative evaluation of
TRAF6 expression in immunohisto-
chemical staining. Date shown repre-
sent mean ± SD. Differences in
TRAF6 expression: * – in reproductive
age women and perimenopausal age
women; a – in small myomas and
healthy myometrium; b – in periphery
of small myomas and healthy
myometrium; c – in large myomas and
healthy myometrium; d – in periphery
of large myomas and healthy
myometrium; e – in small myomas
and its periphery; f – in small myomas
and its periphery, are statistically sig-
nificant.
TRAF6
Comparison of TRAF6 expression levels in myometri-
um of women of various age groups showed that in
samples originating from perimenopausal women it
was even higher, reaching 120% of the value noted in
the younger group. However, the difference proved to
be insignificant.
Expression of TRAF6 measured at the periphery of
myomas originating from uteri of young women
resembled that in the control, amounting to, at most,
110% of the control value.
TRAF6 expression level in small myomas isolated
from uteri of young women was higher than that in the
control and amounted to 125%, but the difference was
insignificant. Even higher level of TRAF6 expression
was seen in large myomas, in which the level of the
discussed TRAF protein reached 135% of the control
level (Fig.6; Table 1).
In analysis of TRAF6 levels in myomas and in the
surrounding myometrium it was demonstrated that in
the group of young women expression of TRAF6 in
small myomas was slightly, but insignificantly higher
than in the surrounding myometrium. A more pro-
nounced difference, of 125% order, was detected dur-
ing analysis differences in TRAF6 expression levels in
large myomas, as compared to those in their direct
neighbourhood.
Analysis of TRAF6 expression in uteri of peri-
menopausal women demonstrated more pronounced
differences: expression of the protein measured at the
periphery of myomas was higher than that in the con-
trol, amounting to 135% and 125% in small and large
myomas, respectively (Fig. 6; Table 1). The difference
was significant for periphery of small myomas.
The detected expression level of the evaluated
TRAF6 protein in small myomas isolated from uteri of
peri-menopausal women was higher than that in the
control, amounting to 135%, and the difference was
significant. In large myomas of the age group the
detected TRAF6 expression level was even slightly
higher, reaching 145% of the control value. 
Evaluation of TRAF6 expression level in myomas
and the surrounding myometrium demonstrated that in
the older age group expression of TRAF6 in small
myomas was the same as in the surrounding myometri-
um. On the other hand, a difference of 115% order was
noted upon analysis of TRAF6 expression in large
myomas. However, the difference was insignificant.
Discussion
Uterine leiomyomas are the most frequent tumours of
female genital tract. More than 70% of preparations,
resulting from hysterectomy performed for various
reasons, demonstrated presence of uterine leiomyomas
[19-21].
Certain traits of TRAF proteins suggest that they
act as cytoplasmic adapters, which may support trans-
duction of an intra-cellular signal due to their capacity
to bind receptors, including their self-recruitment to
the signalling complex. It is known that TRAF pro-
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Table 1. Western blot analysis of TRAF2 protein in uterus tissue samples from myometrium and leiomyomas from young and peri-
menopausal age women. Quantitative analysis indicated, that TRAF2 level in myometrium perimenopausal age women is 107% those in
young women.
Differences in TRAF2 expression: * – in reproductive age women and perimenopausal age women; a in small myomas and healthy myometrium; b in
periphery of small myomas and healthy myometrium; c in large myomas and healthy myometrium; d in periphery of large myomas and healthy myometri-
um; e in small myomas and its periphery, f in large myomas and its periphery, are statistically significant for p=0.05.
Table 2. Western blot analysis of TRAF6 protein in uterus tissue samples from myometrium and leiomyomas from young and peri-
menopausal age women. Quantitative analysis indicated, that TRAF6 level in myometrium perimenopausal age women is 113% those in
young women.
Differences in TRAF6 expression: * – in reproductive age women and perimenopausal age women; a in small myomas and healthy myometrium; b in
periphery of small myomas and healthy myometrium; c in large myomas and healthy myometrium; d in periphery of large myomas and healthy myometri-
um; e in small myomas and its periphery, f in large myomas and its periphery, are statistically significant for p=0.05.
teins may serve in modulation of receptor's capacity to
induce various signalling pathways [22], which lead to
phosphorylation and activation of protein kinases and,
then, to activate transcription factors of, among others,
AP-1 family. 
In our studies we have demonstrated that myome-
tria of myoma-free women manifest evident expres-
sions of TRAF2 and TRAF6 proteins. Their levels were
well marked but similar in samples originating from
young women and women of perimenopausal age (Fig.
2 and 4; Table 1 and 2). This indicates that absence of
diagnosis of myoma presence not necessarily is equiv-
ocal with an absence of neoplastic risk in a patient. A
stable level of TRAF2 and TRAF6 expression repre-
sents a stimulating factor in the NF-κB activation path-
way, which, as generally known, directly affects prolif-
erative processes. Even if neither TRAF2 nor TRAF6
affect directly expression of aromatase, their indirect
effect is evident. As generally known, the two proteins
directly stimulate activity of NF-κB. This nuclear fac-
tor may associate with one of promoters, such as I.4,
which mobilizes aromatase synthesis pathway.
TRAF proteins also seem to play a significant role
in modulation of an early stage in the receptor-induced
activation of NF-κB [9,23,24]. As has been demon-
strated, NF-κB-induced kinase (NIK) represents a part
of the signalling complex, formed by multimerization
of TRAF proteins following recruitment to cell surface
receptors [15,25-27]. An evidence for the ability of
TRAF proteins to affect activation of NF-κB with
receptor mediation has originated from the demonstra-
tion that TRAF2 may inhibit activation of NF-κB in
response to oligomerization of numerous TNFR-linked
molecules, including TNFRII, CD40 and other [28]. In
our studies we have shown that expression of TNF-α
has been increasing in all studied experimental groups
(unpublished data). The cytokine directly activates,
among others, TRAF2. Subsequently we have shown
that also IL-1 reached high levels, particularly in cases
of small and large myomas (unpublished data). In con-
cert with TNF-α the cytokine stimulates TRAF6 [29].
The two studied heretofore proteins exert a direct stim-
ulatory effect on NF-κB activity. This may be synony-
mous to an increased proliferation in the pathologically
altered tissue. However, it is suggested that engage-
ment of the proteins may activate NF-κB in more than
a single pathway. Although certain TRAF, and TRAF2
in particular, activate NF-κB and AP-1, the differential
recruitment of TRAF-activating or TRAF-inhibiting
molecules seems to involve just one of several control
levels in receptor-induced signal transduction. The fact
that TRAF-binding sites in receptors significantly dif-
fer in sequence provides an argument for differences in
affinity of TRAF molecules binding to various receptor
proteins. Moreover, the potential for homo- and/or het-
erodimerization of TRAF molecules, which leads to
formation of higher order complexes might add here
another level of control [12]. It is probable that differ-
ences in levels of TRAF expression and/or depletion of
various TRAF molecules following recruitment to the
receptor and the nature of multimerized, TRAF-recruit-
ing receptor result in formation of various poly-protein
aggregates and these either allow cells to survive or
induce apoptosis [28,30-32].
A few experiments provided the proof for action of
TRAF proteins as mediators of life or death and repre-
sented subsequent steps in understanding the role of
TRAF as one of the key controllers of cell reaction to
stress. The clearly higher levels of TRAF2 and TRAF6
expression, documented in both types of myomas and
at their periphery may corroborate the hypothesis. As
described above, TRAF2 and TRAF6 seem to act as
inducers of positive signals for cell growth and prolif-
eration, with mediation of kinase cascades and induc-
tion of NF-κB-controlled genes [33]. When the mole-
cules are available in significant quantities, activation
of TNFR seems to promote stress response. In con-
trast, in cells in which the factors are depleted or
blocked by inhibitors, the apoptotic response is
favoured [28,30-32]. Thus, availability of TRAF pro-
teins and their activity may regulate the key point of
cell survival, involving on one hand stress response
and, on the other, a programmed cell death.
The data provide proof for important role of
TRAF2 in activation of JNK pathway through TNFR.
Even if experiments in tissue culture systems indicate
that TRAF2 may control activation of NF-κB, exis-
tence of TRAF-independent pathways has been
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Fig. 5. There is Western blot analysis of TRAF2 in myometri-
um and leiomyoma tissue from reproductive age women and peri-
menopausal age women. Lane 1 – control; lane 2 – small myomas;
lane 3- periphery of small myomas; lane 4 – large myomas; lane 
5 – periphery of large myomas.Samples (25 μg/lane) were elec-
trophoresed, blotted and TRAF2was detected (see Materials and
Methods and Table 1).
Fig. 6. There is Western blot analysis of TRAF6 in myometrium
and leiomyoma tissue from reproductive age women and peri-
menopausal age women. Lane 1 – control; lane 2 – small myomas;
lane 3- periphery of small myomas; lane 4 – large myomas; lane 
5 – periphery of large myomas. Samples (25 μg/lane) were elec-
trophoresed, blotted and TRAF6 was detected (see Materials and
methods and Table 2).
demonstrated. Evidently this might have been expect-
ed since, as we have shown, TRAF2 level in myomas
was lower than the level of TRAF6.
The experiments suggest that TRAF2 may exert
also an anti-apoptotic activity. Studies on cells with
deficiency of TRAF2 confirmed the anti-apoptotic
activity of TRAF2 and its significance for TNF-
induced activation of JNK [34-36]. Thus, even if
TRAF2 manifests an evident anti-apoptotic activity, it
also can bind members of TNFR family to pro-apop-
totic pathways. 
Literature references related to the subject are quite
scanty. In the few studies on local expression of TRAF2
and TRAF6 in uterine myomas an attempt was made to
find out if proteins manifested in myoma cells play a sig-
nificant role in their growth and if myomas synthesize
sufficient amounts of oestrogens for promotion of
myoma growth. Myoma cells are thought to be able to
synthesize appropriate amounts of oestrogens and, more-
over, the local aromatization in myoma tissue is thought
to be responsible for the cell growth-promoting effect.
In our paper we were defining level of TRAF
expression with two techniques. We indicated that pro-
files of quality changes are the same but quantity
changes are different. One can notice that results
received in immunohistochemical stains are visibly
higher than the one received in Western blot method.
Lower values obtained in Western blot method are is
probably caused by the fact that staining in this method
is the applied to whole mass of sample in the distinc-
tion of immunohistochemical staining where its apply
exclusively to cells.
In discussions on TRAF proteins, an important
observation should be taken into account: in our stud-
ies we have noted that in myometria originating from
women with myoma presence, expression of TRAF
proteins has been evident. Its level has been even high-
er than that in myomas and clearly higher than the
level seen in a healthy myometrium. It should be borne
in mind that the samples were isolated outside of the so
called surgical safety margin and, thus, they originated
from the region of uterus, in which no relapse of
myoma should occur. In the region our studies have
documented TRAF protein expression sufficiently
high to warrant in appropriate conditions the develop-
ment of de novo myoma. It remains to be established
how far from the tumorous lesion the level of TRAF
protein expression is sufficient for such a complica-
tion. This requires further studies.
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